PatenSee key facts
as of Oct 2026- Developer of a contactless surveillance system designed to detect the early development of asymptomatic vascular stenosis in hemodialysis patients.
- PatenSee is valued at approximately $7.5M as of Oct 2026, set at its seed round, Feb 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $2.8M across 1 recorded rounds; the latest was Seed Round ($2.0M) in Feb 2025.
- Notable investors include Spark Capital, Innovation Authority, Michigan Rise, Intellectual Ventures, ARC Innovation Center — 10 tracked in total.
- PatenSee has filed 1 Form D with the SEC, most recently Feb 2025 ($1.6M sold to 10 investors).
- Status: Privately Held (backing).
Valued at $7.5M at its seed round, Feb 2025. Nothing has traded since.
- ·Watch PatenSee: the Monday email on marks, rounds and moves
PatenSee funding rounds
1 roundsPatenSee valuation
PatenSee was valued at $7.5 million at its seed round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has PatenSee raised?
PatenSee has raised $2.8 million in total; 1 of its rounds is on record. The largest on record was a $2 million seed round in Feb 2025.
PatenSee has filed 1 Form D with the SEC, most recently in Feb 2025 ($1.6 million sold to 10 investors).
PatenSee investors
10 investors are on record for PatenSee, including Spark Capital, Innovation Authority, Michigan Rise and Intellectual Ventures. The seed round in Feb 2025 drew 4 investors.
Comparable companies
Comparable monitoring equipment names by valuation on PrivateMarketView: JuneBrain ($9.9 million), Kegg ($9.3 million) and Aspect Health ($2 million).
About PatenSee
Developer of a contactless surveillance system designed to detect the early development of asymptomatic vascular stenosis in hemodialysis patients. The company's technology uses advanced, multi-modal imaging technologies and machine learning and is seamlessly integrated into the clinic workflow and detects early signs of vascular access stenosis to permit preventative and cost-effective intervention, enabling care teams to perform interventions to protect the patient's hemodialysis lifeline, improve quality of care and prolong life expectancy.
- Industry
- Monitoring Equipment
- Sector
- Healthcare
- HQ
- Or Yehuda, Israel
- Founded
- 2019
- Employees
- 9
- Website
- patensee.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.